METTL14 modulates glycolysis to inhibit colorectal tumorigenesis in p53‐wild‐type cells
Sign Up to like & getrecommendations! Published in 2023 at "EMBO Reports"
DOI: 10.15252/embr.202256325
Abstract: The frequency of p53 mutations in colorectal cancer (CRC) is approximately 40–50%. A variety of therapies are being developed to target tumors expressing mutant p53. However, potential therapeutic targets for CRC expressing wild‐type p53 are… read more here.
Keywords: p53 crc; p53; p53 wild; wild type ... See more keywords